15 Nov 20 | US | Genentech files a complaint against Centus Biotherapeutics, Fujifilm Kyowa Kirin Biologics, Fujifilm Corp and Kyowa Kirin relating to its proposed bevacizumab biosimilar. Genentech asserts that Centus failed to provide sufficient information for G...

Significant biosimilar activities this week include:

  • 22 Oct 20: Ph III clinical trials of FYB202 (proposed ustekinumab biosimilar developed by Formycon and Bioeq) commenced recruiting in Poland
     

  • 26 Oct 20: Samsung Bioepis announced results from two post-mar...

Significant biosimilar activities this week include:

  • 11 Aug 20:  in an online press conference, Samsung Biologics announced it plans  for a fourth manufacturing plant within the year.  This new US $2 billion plant will have 256KL capacity, with manufacturing activit...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags